Condition: AIDS-Related Diffuse Large B-cell Lymphoma · AIDS-Related Non-Hodgkin Lymphoma · HIV Infection · Sponsor: AIDS Malignancy Consortium
This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory). T cells are infection fighting blood cells that can kill tumor cells. Axicabtagene ciloleucel consists of genetically modified T cells, modified to recognize CD-19, a protein on the surface of cancer cells. These CD-19-specific T cells may help the body's immune system identify and kill CD-19-positive B-cell non-Hodgkin lymphoma cells.
This description comes directly from the study's public registry record.
Ariela Noy · 646-608-3727 · noya@mskcc.org
Always discuss trial participation with your own doctor first.
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Recruiting |
| University of Illinois at Chicago | Chicago, Illinois, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Montefiore Medical Center - Moses Campus | The Bronx, New York, United States | Recruiting |
| The Ohio state University | Columbus, Ohio, United States | Recruiting |
| University of Pennsylvania / Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| Huntsman Cancer Institute, University of Utah | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05077527